Ocular surface squamous neoplasia (OSSN) is the most common nonpigmented ocular surface neoplasm. Interferon-alpha (IFNα)-2b has been proved to be an effective immunotherapeutic agent to treat OSSN. We have used intralesional and topical (36 μg/ml) pegylated (peg) IFNα-2a to treat a recurrent surgically failed case of OSSN instead of IFNα-2b. In this case report, we have shared our initial experience with the novel use of peg-IFNα-2a to treat OSSN. According to our brief clinical experience, peg-IFNα-2a is nontoxic to ocular surface and has a promising role to treat OSSN.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979401 | PMC |
| http://dx.doi.org/10.4103/ojo.ojo_146_21 | DOI Listing |
Publication Analysis
Top Keywords
ocular surface
16
treat ossn
12
surface squamous
8
squamous neoplasia
8
ossn
5
pegylated interferon-alpha-2a
4
interferon-alpha-2a treatment
4
ocular
4
treatment ocular
4
surface
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!